Caution urged as commercial cancer gene tests gather speed

WOMEN concerned about a family history of breast cancer should be wary of results from multi-gene panel testing because not all “suspect gene” mutations are proven to increase risk, a leading geneticist says.

Professor Ian Campbell, head of the Peter MacCallum Cancer Centre’s genetic cancer research laboratory, says the risk from a small number of gene mutations, including BRAC1 and BRAC2, is established, but evidence of the cancer risk associated with other genes included in commercial tests available on the private market is slim.

He warns that